RxDoctor Payments Data

Benjamin Pulli, MD

Neuroradiology · Stanford, CANPI 1932548179

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $44,571 of the $50,948 with a category attached, or 87.5%. 9 manufacturers reported payments, led by Stryker at 43.5% of the total.

$50,948in general payments, 2019–2025

Across 161 payments — averaging $316.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$22K
  • Qapel Medical Inc$19K
  • Microvention, Inc.$6K
  • Penumbra, Inc.$2K
  • Medtronic$750
  • Route 92 Medical, Inc.$413
  • plus $100 from 3 others
$37,000in research payments, 2019–2025

Across 2 payments — averaging $18,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Nuvascular Inc.$37K

What the payments were for

  • Consulting fees$44,57187%
  • Travel & lodging$1,1452%
  • Food & beverage$5,23210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,948 in reported general payments places this provider in the 85th percentile of 154 neuroradiology providers in California.

See all neuroradiology providers in California

Medicare billing

Part B allowed, 2024
$79,624
Medicare patients
125
Services billed
395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate14$96

Paid to pharmacies, not to this prescriber.

Other neuroradiology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →